학술논문
Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
MAJOR ARTICLE
MAJOR ARTICLE
Document Type
Academic Journal
Author
De Castro, Nathalie; Chazallon, Corine; N'takpe, Jean-Baptiste; Timana, Isabel; Escada, Rodrigo; Wagner, Sandra; Messou, Eugene; Eholie, Serge; Bhatt, Nilesh; Khosa, Celso; Laureillard, Didier; Chau, Giang Do; Veloso, Valdilea G.; Delaugerre, Constance; Anglaret, Xavier; Molina, Jean-Michel; Grinsztejn, Beatriz; Marcy, Olivier
Source
Open Forum Infectious Diseases. December 2022, Vol. 9 Issue 12
Subject
Language
English
ISSN
2328-8957
Abstract
Tuberculosis remains a major cause of morbidity and the leading cause of death in people with human immunodeficiency virus (PWH). In 2020, 214 000 of the 680 000 deaths reported [...]
Background. In people with human immunodeficiency virus [HIV] presenting with advanced disease, rates of virologic success may be lower than expected. The Reflate TB2 trial did not show non-inferiority of raltegravir versus efavirenz in people with HIV (PWH) treated for tuberculosis. We aimed to identify factors associated with virologic success and higher adherence in the trial. Methods. In this analysis, we included participants enrolled in the Reflate TB2 trial with adherence data available. The primary outcome was virologic success (HIV-1 ribonucleic acid [RNA] Results. Four hundred forty-four participants were included in the present analysis. Over the 48-week follow-up period, 290 of 444 (65%) participants had a pill count adherence ratio [greater than or equal to] 95%. At week 48, 288 of 444 (65%) participants were in virologic success. In the multivariate analysis, female sex (adjusted odds ratio [aOR], 1.77; 95% confidence interval [CI], 1.16-2.72; P = .0084), lower baseline HIV-1 RNA levels ( Conclusions. In PWH with tuberculosis receiving raltegravir or efavirenz-based regimens, female sex, optimal adherence, and baseline HIV-1 RNA Keywords. adherence; HIV viral load; raltegravir; tuberculosis.
Background. In people with human immunodeficiency virus [HIV] presenting with advanced disease, rates of virologic success may be lower than expected. The Reflate TB2 trial did not show non-inferiority of raltegravir versus efavirenz in people with HIV (PWH) treated for tuberculosis. We aimed to identify factors associated with virologic success and higher adherence in the trial. Methods. In this analysis, we included participants enrolled in the Reflate TB2 trial with adherence data available. The primary outcome was virologic success (HIV-1 ribonucleic acid [RNA] Results. Four hundred forty-four participants were included in the present analysis. Over the 48-week follow-up period, 290 of 444 (65%) participants had a pill count adherence ratio [greater than or equal to] 95%. At week 48, 288 of 444 (65%) participants were in virologic success. In the multivariate analysis, female sex (adjusted odds ratio [aOR], 1.77; 95% confidence interval [CI], 1.16-2.72; P = .0084), lower baseline HIV-1 RNA levels ( Conclusions. In PWH with tuberculosis receiving raltegravir or efavirenz-based regimens, female sex, optimal adherence, and baseline HIV-1 RNA Keywords. adherence; HIV viral load; raltegravir; tuberculosis.